Miacalcic

Calcitonin salmon, the active ingredient in Miacalcic, is a calcitonin presented as an injectable formulation for intramuscular, intravenous or subcutaneous use. It treats osteoporosis in postmenopausal women, Paget's disease of bone, and hypercalcemia of malignancy.

GNH USA supplies Miacalcic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miacalcic is a calcitonin analogue that acts on bone metabolism disorders. It is indicated for the following conditions: - Osteoporosis in postmenopausal women: reduces bone resorption to improve bone density and lower fracture risk. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain. - Hypercalcemia of malignancy: lowers serum calcium levels by inhibiting osteoclast activity and increasing renal calcium excretion.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Flushing: transient redness and warmth, often on the face. - Headache: mild to moderate intensity. - Injection site reactions: pain, erythema, or swelling at the administration site. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypocalcemia: marked reduction in serum calcium that may cause muscle cramps or tetany. - Osteosarcoma: extremely rare malignant bone tumor reported with long‑term use. - Severe hypotension: sudden drop in blood pressure, especially with rapid IV administration. - Seizures: rare neurologic events possibly related to electrolyte disturbances.

Before using Miacalcic, consider the following precautions: - Renal impairment: monitor calcium and renal function closely. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant calcium supplements: may diminish therapeutic effect; adjust dosing as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Miacalcic may interact with several medications. Review the following groups:

Major Interactions (Avoid): - Calcium supplements: can antagonize calcitonin’s calcium‑lowering effect. - Bisphosphonates: concurrent use may increase risk of severe hypocalcemia. - Loop diuretics: may potentiate calcium loss and exacerbate hypocalcemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce the therapeutic response to calcitonin. - Estrogen therapy: may have additive effects on bone density, requiring monitoring. - Antihypertensive agents: monitor blood pressure if calcitonin is given intravenously rapidly.